Back to Journals » Journal of Blood Medicine » Volume 1

Cinryze™ as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety

Authors Lunn M, Santos C, Craig T

Published 24 August 2010 Volume 2010:1 Pages 163—170


Review by Single-blind

Peer reviewer comments 2

Michael Lunn1, Carah Santos2, Timothy Craig1
1Penn State Hershey Section of Allergy, Asthma and Immunology, Hershey, PA USA; 2Stanford University Department of Pediatrics, Palo Alto, CA USA

Abstract: Hereditary angioedema (HAE) is a clinical disorder characterized by a deficiency of C1 esterase inhibitor (C1-INH). HAE has traditionally been divided into two subtypes. Unique among the inherited deficiencies of the complement system, HAE Types I and II are inherited as an autosomal dominant disorder. The generation of an HAE attack is caused by the depletion and/or consumption of C1-inhibitor manifested as subcutaneous or submucosal edema of the upper airway, face, extremities, or gastrointestinal tract. Attacks can be severe and potentially life-threatening, particularly with laryngeal involvement. Despite the availability of C1-INH for the treatment of HAE since the 1980s in Europe and other countries, HAE treatment in the United States was limited to androgen therapy. The human plasma-derived C1 esterase ­inhibitor (CinryzeTM), distributed by Lev Pharmaceuticals, was approved in October 2008 for the ­prevention of HAE attacks based on the results of a phase III clinical trial. This review aims to describe the history of C1-INH replacement in HAE as well as the pharmacology, efficacy and safety of C1-INH, concentrating on Cinryze as the first approved chronic replacement treatment for the prophylaxis of HAE attacks.

Keywords: hereditary angioedema, C1 esterase inhibitor, Cinryze, prophylaxis, angioedema

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]